Hoth Therapeutics HOTH 深 沪
已收盘 09-19 16:00:00 美东时间
0.98
-0.030
-2.97%
华盛通- 最 高1.00
- 今 开1.00
- 成交量 32.85万股
- 最 低 0.9401
- 昨 收 1.01
- 总市值 425.95万
- 52周最高 1.73
- 市盈率 静 --
- 换手率 7.56%
- 52周最低 0.58
- 委 比 -73.75%
- 总股本 434.64万
- 历史最高 347.00
- 量 比 0.13
- 振 幅 5.93%
- 历史最低 0.58
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多诺瓦瓦克斯医药盘中异动 临近午盘股价大涨5.15%报13.88美元
北京时间2024年09月17日23时32分，诺瓦瓦克斯医药（NVAX.us）股票出现异动，股价急速拉升5.15%。截至发稿，该股报13.88美元/股，成交量2...
09-17 23:32
杰龙盘中异动 快速拉升5.03%
北京时间2024年09月17日22时23分，杰龙（GERN.us）股票出现波动，股价快速拉升5.03%。截至发稿，该股报4.59美元/股，成交量126.978万...
09-17 22:23
快讯 | hoth therapeutics宣布ht-alz的阿尔茨海默病药物预临床结果令人振奋
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug ...
09-17 19:57
EF Hutton Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
EF Hutton analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.
09-06 03:06
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-16 18:28
快讯 | hoth therapeutics和aronnax公司签订HT-Kit癌症治疗的主要服务协议
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement for Ht-Kit C...
08-15 20:04
Market-Moving News for July 24th
TSLA: -8.8% | Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume growth lower than 2023. HOTH: 95% | Hoth Therapeutics signs Agreement With LTS
07-24 20:34
快讯 | hoth therapeutics扩大了癌症患者的临床试验
Hoth Therapeutics Expands Clinical Trial for Cancer Patients
07-16 20:32
Hoth Therapeutics announces JD with Wise Systems International
Hoth Therapeutics (NASDAQ:HOTH) announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvid...
06-10 21:18
Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?
Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neurokinin 1 Receptor pathway. HT-ALZ exhibits significant reductions in soluble Aβ levels, alleviates anxiety, and enhances cognitive function in preclinical models.
03-20 01:01
